{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:11:47Z","timestamp":1761743507064},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1097\/maj.0b013e31821a520e","type":"journal-article","created":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T12:22:17Z","timestamp":1307103737000},"page":"73-75","source":"Crossref","is-referenced-by-count":8,"title":["Rhabdomyolysis in a 48-Year-Old Man With Hepatitis B-Induced Cirrhosis"],"prefix":"10.1016","volume":"342","author":[{"given":"Shuangsuo","family":"Dang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/MAJ.0b013e31821a520e_bb0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2893.2010.01274.x","article-title":"Management of chronic hepatitis B: experience from China","volume":"17","author":"Sun","year":"2010","journal-title":"J Viral Hepatitis"},{"key":"10.1097\/MAJ.0b013e31821a520e_bb0015","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.2174\/092986706778521995","article-title":"Treating chronic hepatitis B: today and tomorrow","volume":"13","author":"Borgia","year":"2006","journal-title":"Curr Med Chem"},{"key":"10.1097\/MAJ.0b013e31821a520e_bb0020","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1128\/AAC.46.6.1728-1733.2002","article-title":"Pharmacology of beta-L-thymidine and beta-L-2\u2032-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus","volume":"46","author":"Hernandez-Santiago","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1097\/MAJ.0b013e31821a520e_bb0025","series-title":"Antiviral beta-L-nucleosides specific for hepatitis B virus infection.","author":"Sommadossi","year":"2002"},{"key":"10.1097\/MAJ.0b013e31821a520e_bb0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1128\/AAC.45.1.229-235.2001","article-title":"Antiviral L-nucleosides specific for hepatitis B virus infection","volume":"45","author":"Bryant","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1097\/MAJ.0b013e31821a520e_bb0035","first-page":"222a","article-title":"Two-year results from the globe trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LDT) vs. lamivudine","volume":"44","author":"Lai","year":"2006","journal-title":"Hepatology"},{"key":"10.1097\/MAJ.0b013e31821a520e_bb0040","series-title":"Abstract from the 19th Asian Pacific Association for the study of the liver (APASL)","article-title":"Absence of mitochondrial toxicity of telbuvidine in skeletal muscle cells, hepatocytes, and neuronal cells from rat or human","author":"Weaver","year":"2009"},{"key":"10.1097\/MAJ.0b013e31821a520e_bb0045","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1128\/AAC.00029-08","article-title":"Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B","volume":"52","author":"Bridges","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1097\/MAJ.0b013e31821a520e_bb0050","doi-asserted-by":"crossref","first-page":"6150","DOI":"10.3748\/wjg.13.6150","article-title":"Telbivudine: a new treatment for chronic hepatitis B","volume":"13","author":"Amarapurkar","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1097\/MAJ.0b013e31821a520e_bb0055","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12325-009-0004-y","article-title":"Telbivudine in the treatment of chronic hepatitis B","volume":"26","author":"Nash","year":"2009","journal-title":"Adv Ther"},{"key":"10.1097\/MAJ.0b013e31821a520e_bb0060","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jhep.2009.06.011","article-title":"Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B","volume":"51","author":"Fleischer","year":"2009","journal-title":"J Hepatol"},{"key":"10.1097\/MAJ.0b013e31821a520e_bb0065","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","article-title":"2-year GLOBE Trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B","volume":"136","author":"Liaw","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1097\/MAJ.0b013e31821a520e_bb0070","series-title":"Poster #PE 140 presented at the 19th Asian Pacific Association for the study of the liver (APASL","article-title":"CK elevation during chronic hepatitis B (CHB) treatment with telbivudine: experience from the combined globe (NV-02B-007\/CLDT600A2302) and NV-02B-015 (015) study clinical safety database","author":"Avila","year":"2009"},{"key":"10.1097\/MAJ.0b013e31821a520e_bb0075","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0168-8278(09)60909-0","article-title":"Increased risk with combination of telbivudine and pegylated-interferon alfa-2A in study CLDT600A2406, compared to uncommon rate with telbivudine monotherapy from the Novartis global database","volume":"50","author":"Goncalves","year":"2009","journal-title":"J Hepatol"},{"key":"10.1097\/MAJ.0b013e31821a520e_bb0080","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug-reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915312489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915312489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,2]],"date-time":"2018-12-02T06:22:58Z","timestamp":1543731778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915312489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0002962915312489"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e31821a520e","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}